

About Us



a subsidiary of SK biopharmaceuticals

We are part of SK Biopharmaceuticals, a growing biotech company focused on discovering and developing transformative therapies.

Our proprietary **MO**lecular **P**roximity **E**nabled **D**etection (MOPED™) molecular glue platform complements SK Life Science Labs' core targeted protein degradation (TPD) platform.

By leveraging our cutting-edge platforms and harnessing our deep drug-hunting expertise, we are determined to build a future where we'll change the outcome of currently life-altering diseases.

Our Pipeline

SK Life Science Labs' pipeline and platforms are well-positioned for partnering opportunities.



COMPOUND	INDICATION	PRECLINICAL	IND ENABLING
p300	Oncology		
Heterobifunctional Target	Oncology		
Molecular Glue Target	Oncology		

Targeted Protein Degradation

The Ubiquitin Proteasome (UPS) is responsible for the critical cellular process of protein degradation, essential for maintaining cellular homeostasis. This process can be hijacked to remove disease causing proteins.

A drug-like protein degrader (step 1) binds a target Protein of Interest (POI) and an E3 to bring them together resulting in the formation of a ternary complex (step 2). This facilitates the attachment of multiple ubiquitin tags to the POI (step 3) marking it for rapid degradation by the Proteasome (step 4). The degrader survives this process (step 5) allowing it to target additional copies of the same POI for destruction.

SK Life Science Labs utilizes this targeted approach to design degrader medicines that will treat debilitating diseases to improve the lives of patients.




p300

The p300 histone acetyltransferase is implicated in oncogenic processes that drive a variety of solid and liquid cancers. p300 functions as a coactivator of many transcription factors by acetylating histones and allowing for the transcription of many genes including oncogenic drivers. Selective degradation of p300 results in removal of histone acetylation marks, inactivates transcription, and thereby repression of key oncogenes known to promote tumorigenesis, yet spares normal tissue. p300 degradation leads to significant reduction of tumor growth in preclinical models and is currently in IND-enabling studies.

MOPED™

SK Life Science Labs expands access to target biology accessible by TPD. Our **MO**lecular **PRO**ximity **E**nabled **D**etection (MOPED™) platform uses an exquisitely sensitive induced proximity assay to discover glues between targets and E3s. With a library of >30 E3s, glue hits for multiple targets and multiple E3s have been discovered, and cellular degradation has been confirmed. With its unparalleled flexibility, MOPED™ can be configured to screen for any induced proximity mechanism.



Contact Us

Strategic Alliance & Partnership Opportunities
Partnerships@SKSLabs.com

For more information, visit us at: www.skslabs.com

Media Inquiries & PR
Media@SKSLabs.com

General Business
Info@SKSLabs.com